Hyperthermia-regulated immunogene therapy

International Journal of Hyperthermia

Volumn 18, Issue 6, 2002, Pages 586-596

  Li, C Y ^a   Dewhirst, M W ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Cytokine gene therapy; Gene therapy; Heat inducible promoter; Hyperthermia

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; HEAT SHOCK PROTEIN; HUMAN GROWTH HORMONE; IMMUNOLOGIC AGENT; INTERLEUKIN 12; INTERLEUKIN 2; MIFEPRESTONE; MURISTERONE; RAPAMYCIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROMOTER; UNCLASSIFIED DRUG;

CANCER; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CYTOTOXICITY; EXPERIMENTAL MODEL; FEASIBILITY STUDY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HEAT; HEAT SHOCK RESPONSE; HUMAN; HYPERTHERMIC THERAPY; IMMUNOTHERAPY; MEDICAL RESEARCH; NONHUMAN; REPORTER GENE; REVIEW; SUICIDE GENE THERAPY; TEMPERATURE; THERMOREGULATION; ANIMAL; NEOPLASM;

ANIMALS; GENE THERAPY; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOTHERAPY; NEOPLASMS;

EID: 0036863419     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/0265673021000017082     Document Type: Review

References (45)

1. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-13.
2. Huber BE, Richards CA, Austin EA. Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann NY Acad Sci 1994; 716: 104-14; discussion 140-103.
3. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-7.
4. Moolten FL, Vonderhaar BK, Mroz PJ. Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Hum Gene Ther 1996; 7: 1197-204.
5. Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A, Aukerman SL, Pierce GF. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 1999; 59: 2608-14.
6. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther 2001; 3: 105-12.
7. Chandler LA, Doukas J, Gonzalez AM, Hoganson DK, Gu DL, Ma C, Nesbit M, Crombleholme TM, Herlyn M, Sosnowski BA, Pierce GF. FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther 2000; 2: 153-60.
8. Doukas J, Hoganson DK, Ong M, Ying W, Lacey DL, Baird A, Pierce GF, Sosnowski BA. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. Faseb J 1999; 13: 1459-66.
9. Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, Bergelson JM, Currier MA. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 2953-60.
10. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-51.
11. Gossen M, Bujard H. Anhydrotetracycline, a novel effector for tetracycline controlled gene expression systems in eukaryotic cells. Nucleic Acids Res 1993; 21: 4411-2.
12. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-9.
13. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996; 93: 3346-51.
14. Tsai SY, O'Malley BW, DeMayo FJ, Wang Y, Chua SS. A novel RU486 inducible system for the activation and repression of genes. Adv Drug Deliv Rev 1998; 30: 23-31.
15. Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci USA 2000; 97: 13221-6.
16. Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther 1995; 6: 1507-13.
17. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-91.
18. Seung LP, Mauceri HJ, Beckett MA, Hallahan DE, Hellman S, Weichselbaum RR. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res 1995; 55: 5561-5.
19. Scott SD, Marples B, Hendry JH, Lashford LS, Embleton MJ, Hunter RD, Howell A, Margison GP. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther 2000; 7: 1121-5.
20. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000; 7: 511-7.
21. Marples B, Greco O, Joiner MC, Scott SD. Molecular approaches to chemo-radiotherapy. Eur J Cancer 2002; 38: 231-9.
22. Luna MC, Ferrario A, Wong S, Fisher AM, Gomer CJ. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res 2000; 60: 1637-44.
23. Luna MC, Chen X, Wong S, Tsui J, Rucker N, Lee AS, Gomer CJ. Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. Cancer Res 2002; 62: 1458-61.
24. Hogset A, Prasmickaite L, Tjelle TE, Berg K. Photochemical transfection: A new technology for light-induced, site-directed gene delivery. Hum Gene Ther 2000; 11: 869-80.
25. Morimoto R, Tissieres A, Georgopoulos C, eds. Stress Proteins in Biology and Medicine, Cold Spring Harbor; Cold Spring Harbor Laboratory Press, 1990.
26. Dreano M, Brochot J, Myers A, Cheng-Meyer C, Rungger D, Voellmy R, Bromley P. High-level, heat-regulated synthesis of proteins in eukaryotic cells. Gene 1986; 49: 1-8.
27. Borrelli MJ, Schoenherr DM, Wong A, Bernock LJ, Corry PM. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells. Cancer Res 2001; 61: 1113-21.
28. Brade AM, Ngo D, Szmitko P, Li PX, Liu FF, Klamut HJ. Heat-directed gene targeting of adenoviral vectors to tumor cells. Cancer Gene Ther 2000; 7: 1566-74.
29. Gerner EW, Hersh EM, Pennington M, Tsang TC, Harris D, Vasanwala F, Brailey J. Heat-inducible vectors for use in gene therapy. Int J Hyperthermia 2000; 16: 171-81.
30. Blackburn RV, Galoforo SS, Corry PM, Lee YJ. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res 1998; 58: 1358-62.
31. Braiden V, Ohtsuru A, Kawashita Y, Miki F, Sawada T, Ito M, Cao Y, Kaneda Y, Koji T, Yamashita S. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter. Hum Gene Ther 2000; 11: 2453-63.
32. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, Di Tomaso E, Brown EB, Izumi Y, Campbell RB, Berk DA, Jain RK. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001; 98: 4628-33.
33. McGuire S, Zaharoff D, Yuan F. Interstitial transport of macromolecules, implications for delivery of nucleic acids into solid tumors. In Pharmaceutical Perspectives of Nucleic Acids Based Therapy. Mahato R, Kim S, eds, London: Taylor & Francis, 2002; 434-54.
34. Huang Q, Hu JK, Lohr F, Zhang L, Braun R, Lanzen J, Little JB, Dewhirst MW, Li CY. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 2000; 60: 3435-9.
35. Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, Dewhirst MW, Li CY. Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys 2000; 48: 1513-8.
36. Lohr F, Huang Q, Hu K, Dewhirst M, Li C-Y. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clinical Cancer Research 2001.
37. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997; 15: 953-960.
38. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000; 60: 1009-13.
39. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001; 7: 2887-97.
40. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61: 6428-36.
41. Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol 1999; 15: 769-73.
42. Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, Dewhirst MW, Li CY. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000; 2: 195-203.
43. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
44. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-504.
45. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-3.